* Infants weighing at least 2,000 g and born to mothers with an unknown HBsAg status: Administer the hepatitis B vaccine within 12 hours of birth and HBIG
by hospital discharge or age 7 days (whichever is first) if HBsAg status remains unknown or is confirmed positive.
Caption: Figure 2: Pharmacokinetic (PK) parameters of a hepatitis B immune globulin (HBIG
) product in pregnant and nonpregnant guinea pigs.
The mechanism for controlling HBV viral recurrence is direct viral replication control by a combination of NAs and HBIG
as passive immunoprophylaxis .
administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG
The rate of protection observed in infants who received only the vaccine was statistically similar to that of infants who received the vaccine plus hepatitis B immune globulin (HBIG
Materials and Methods: The first group (n=28) received a double dose of hepatitis B vaccine at 0, 1, 2 and 6 months and immunoglobin (HBIG
) at 0 and 1 month concurrently with vaccine but at a different intramuscular site.
In the United Kingdom, babies at highest risk for infection, those born to mothers whose serum does not contain anti-HBe, are offered additional passive immunization prophylaxis (10) with 200 IU of hepatitis B immunoglobulin (HBIg
) within 24 hours of delivery.
If mother's HbsAg is positive give HBIG
within 12 hours or up to 7 days.
Organ Transplant Medications (anti-rejection and other) Neoral or Prograf $1,500/month Cellcept $800/month Septra $7.50/month Prednisone $5.50/month Proton pump inhibitor $160/month Nystatin $172/month Valcyte $2,000/month HBIG
5 cc vial $2,190/month Total $6835 Table 7.
For non-responders: Persons who are non-responders should be considered susceptible to HBV and should be counseled regarding precautions to prevent HBV infection and the need to obtain HBIG
prophylaxis for any known or probable parenteral exposure to hepatitis B surface antigen (HBsAg)-positive blood.
Food and Drug Administration for the prevention of Hepatitis B is hepatitis B immune globin (HBIG
Immunization can prevent development of the persistent carrier state in 70-90% of infants of carrier mothers, and protection can increase to 85-90% when hepatitis B immunoglobulin (HBIg
) is administered within 24 hr of birth together with the first dose of vaccine (13).
The product, hepatitis B immune globulin (HBIG
), is given simultaneously with HBV vaccine to newborn infants whose mothers are HBsAg positive, or postneedle stick or after sexual exposure in adults who are not immune to HBV .